BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34773473)

  • 41. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of
    Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
    BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
    Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
    [TBL] [Abstract][Full Text] [Related]  

  • 45.
    Wang R; Shen G; Yang R; Ma X; Tian R
    Eur J Radiol; 2020 Sep; 130():109131. PubMed ID: 32622250
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A
    BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of
    Diego RPS; Rádis-Baptista G; Filho RVAO; de Albuquerque ETB; de Castro JDV; Dos Santos KM; de Lucena Santos JÂ; da Silveira Oliveira GF; de Lucena Santos PÂ
    Curr Radiopharm; 2022; 15(3):228-235. PubMed ID: 35209836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection Efficacy of
    Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
    J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
    Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential Impact of
    Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative study of the most commonly-used radiopharmaceuticals for PSMA prostate PET/CT imaging.
    Pasini E; Panagiotidis E; Zoglopitou LA; Kalathas T; Makridou A; Chatzipavlidou V
    Hell J Nucl Med; 2022; 25(1):83-87. PubMed ID: 35388805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intraindividual comparison between
    Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of
    Bailey J; Piert M
    Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical Recurrence of Prostate Cancer: Initial Results with [
    Giesel FL; Will L; Kesch C; Freitag M; Kremer C; Merkle J; Neels OC; Cardinale J; Hadaschik B; Hohenfellner M; Kopka K; Haberkorn U; Kratochwil C
    J Nucl Med; 2018 Apr; 59(4):632-635. PubMed ID: 29419475
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamic patterns of [
    Alberts I; Sachpekidis C; Gourni E; Boxler S; Gross T; Thalmann G; Rahbar K; Rominger A; Afshar-Oromieh A
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):160-167. PubMed ID: 31628514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined whole-body dynamic and static PET/CT with low-dose [
    Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
    Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.